Product
Supplier
Encyclopedia
Inquiry
Home > News > Pharma News > Chinese researchers identify biomarker for early detection of AD

Chinese researchers identify biomarker for early detection of AD

ECHEMI 2020-04-14

Chinese researchers have identified a neuroimaging biomarker that can facilitate the early detection of Alzheimer's disease (AD).

AD is a chronic neurodegenerative disease characterized by progressive dementia. Neuroimaging techniques such as magnetic resonance imaging (MRI) can help diagnose AD. Accurate data-driven methods that can classify and characterize the neural features of AD would be powerful clinical tools.

Researchers from the Institute of Automation of the Chinese Academy of Sciences and other collaborators found that hippocampal radiomic features can be a promising personalized biomarker for AD.

In their search for suitable biomarkers, researchers proposed a novel hippocampal radiomic biomarker derived from structural MRI and systematically validated its reliability using neuroimaging data from over 1,900 individuals, including more than 700 located at six sites in China and around 1,200 subjects from the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset.

The study showed that hippocampal radiomic features are related to the clinical features and changes in cognition ability. Long-term follow-up data in some hospitals demonstrated that the markers could be used to track the progression of the disease in high-risk subjects.

The research was published in the journal Science Bulletin.

Liu Yong, one of the researchers, said the research represents a large, interdisciplinary and interinstitutional effort between clinicians and researchers to develop and validate an AD neuroimaging biomarker.

The methodology can be extended to the study of other mental diseases. It has important clinical implications as the biomarker is promising for the early clinical diagnosis or prognostic follow-up in AD, Liu said.

Liu's team has dedicated itself to neuroimaging studies of AD that could provide relevant information to clinical practice.

The team is now focusing on further verification work among people with high risks of AD in more clinical centers, Liu added.

Disclaimer: ECHEMI reserves the right of final explanation and revision for all the information.

Looking for chemical products? Let suppliers reach out to you!

Comment
Comment
  • Life Sciences Industry Overview

    The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.
    Published in: June.2026

Trade Alert

Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.